Cite
HARVARD Citation
Guglielmelli, P. et al. (2022). Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI). Leukemia & lymphoma. 63 (1), pp. 189-198. [Online].